DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Interrogating the Safety and Efficacy of a Novel STEAP1 Chimeric Antigen Receptor T-Cell Therapy in Prostate Cancer
In this reporting period, we profiled the spatial expression of human STEAP1 in our novelhumanized STEAP1 knock-in (hSTEAP1-KI) mice. We identified human STEAP1 expression in theprostate and adrenal gland of male hSTEAP1-KI mice and further localized expression toluminal prostate epithelial cells and adrenal cortical cells. The hSTEAP1-KI mouse model wasengrafted with the RM9 mouse prostate cancer cell line engineered to express human STEAP1 andwas treated with mouse STEAP1 CAR T cells. These studies demonstrated antitumor activity andpreliminary safety of STEAP1 CAR T cell therapy as no premature deaths, weight loss, or ontargetoff-tumor toxicities specific to STEAP1 CAR T cells were appreciated. We did observeantigen escape as a mechanism of treatment resistance. To address this, we combined STEAP1CAR T cell therapy with collagen binding domain (CBD)-IL-12 fusion cytokine therapy todemonstrate enhanced therapeutic efficacy by broadening the antitumor response and inducingepitope spreading.
Approved For Public Release